Molecular Cancer Therapeutics Chemical and Biological Aspects of Inflammation and Cancer Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hector, S.
Right arrow Articles by Pendyala, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hector, S.
Right arrow Articles by Pendyala, L.
Mol Cancer Ther. 2004;3:813-822
© 2004 American Association for Cancer Research

Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase

Suzanne Hector1, Carl W. Porter2, Debora L. Kramer2, Kimberly Clark1, Joshua Prey1, Nicholas Kisiel2, Paula Diegelman2, Ying Chen2 and Lakshmi Pendyala1

Departments of 1 Medicine and 2 Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York

Requests for reprints: Lakshmi Pendyala, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263. Phone: 716-845-3287; Fax: 716-845-1659. E-mail: lakshmi.pendyala{at}roswellpark.org

A great deal of experimental evidence connects induction of polyamine catabolism via spermidine/spermine N1-acetyltransferase (SSAT) to antiproliferative activity and apoptosis. Following our initial observation from gene expression profiling that platinum drugs induce SSAT, we undertook this present study to characterize platinum drug induction of SSAT and other polyamine catabolic enzymes and to examine how these responses might be enhanced with the well-known inducer of SSAT and clinically relevant polyamine analogue, N1,N11-diethylnorspermine (DENSPM). The results obtained in A2780 ovarian cancer cells by real-time quantitative RT-PCR and Northern blot analysis show that a 2-hour exposure of A2780 cells to platinum drugs induces expression of SSAT, a second SSAT (SSAT-2), spermine oxidase, and polyamine oxidase in a dose-dependent manner. At equitoxic doses, oxaliplatin is more effective than cisplatin in SSAT induction. The most affected enzyme, SSAT, increased 15-fold in mRNA expression and 2-fold in enzyme activity. When combined with DENSPM to further induce SSAT and to enhance conversion of mRNA to activity, oxaliplatin increased SSAT mRNA 50-fold and activity, 210-fold. Polyamine pools declined in rough proportion to levels of SSAT induction. At pharmacologically relevant oxaliplatin exposure times (20 hours) and drug concentrations (5 to 15 µmol/L), these responses were increased even further. Combining low-dose DENSPM with oxaliplatin produced a greater than additive inhibition of cell growth based on the sulforhodamine-B assay. Taken together, the findings confirm potent induction of polyamine catabolic enzymes, such as SSAT by platinum drugs, and demonstrate that these biochemical responses as well as growth inhibition can be potentiated by co-treatment with the polyamine analogue DENSPM. With appropriate in vitro and in vivo optimization, these findings could lead to clinically relevant therapeutic strategies.


Key Words: cisplatin • oxaliplatin • platinum • polyamines • spermidine/spermine N1-acetyltransferase • N1,N11-diethylnorspermine

Grant support: CA-22153, CA-76428, and CA-16056.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 12/24/03; revised 3/23/04; accepted 5/ 4/04.




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. E. Pegg
Spermidine/spermine-N1-acetyltransferase: a key metabolic regulator
Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E995 - E1010.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. L. Kramer, P. Diegelman, J. Jell, S. Vujcic, S. Merali, and C. W. Porter
Polyamine Acetylation Modulates Polyamine Metabolic Flux, a Prelude to Broader Metabolic Consequences
J. Biol. Chem., February 15, 2008; 283(7): 4241 - 4251.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. J. Butcher, G. M. Broadhurst, and R. F. Minchin
Polyamine-dependent Regulation of Spermidine-Spermine N1-Acetyltransferase mRNA Translation
J. Biol. Chem., September 28, 2007; 282(39): 28530 - 28539.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
W. L. Allen, E. G. McLean, J. Boyer, A. McCulla, P. M. Wilson, V. Coyle, D. B. Longley, R. A. Casero Jr., and P. G. Johnston
The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells
Mol. Cancer Ther., January 1, 2007; 6(1): 128 - 137.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Babbar, A. Hacker, Y. Huang, and R. A. Casero Jr.
Tumor Necrosis Factor {alpha} Induces Spermidine/Spermine N1-Acetyltransferase through Nuclear Factor {kappa}Bin Non-small Cell Lung Cancer Cells
J. Biol. Chem., August 25, 2006; 281(34): 24182 - 24192.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Rodriguez-Caso, R. Montanez, M. Cascante, F. Sanchez-Jimenez, and M. A. Medina
Mathematical Modeling of Polyamine Metabolism in Mammals
J. Biol. Chem., August 4, 2006; 281(31): 21799 - 21812.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Boyer, W. L. Allen, E. G. McLean, P. M. Wilson, A. McCulla, S. Moore, D. B. Longley, C. Caldas, and P. G. Johnston
Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.
Cancer Res., March 1, 2006; 66(5): 2765 - 2777.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
Y. Wang and R. A. Casero Jr.
Mammalian Polyamine Catabolism: A Therapeutic Target, a Pathological Problem, or Both?
J. Biochem., January 1, 2006; 139(1): 17 - 25.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
G. Marverti, M. G. Monti, A. E. Pegg, D. E. McCloskey, S. Bettuzzi, A. Ligabue, A. Caporali, D. D'Arca, and M. S. Moruzzi
Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin
Carcinogenesis, October 1, 2005; 26(10): 1677 - 1686.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Kee, B. A. Foster, S. Merali, D. L. Kramer, M. L. Hensen, P. Diegelman, N. Kisiel, S. Vujcic, R. V. Mazurchuk, and C. W. Porter
Activated Polyamine Catabolism Depletes Acetyl-CoA Pools and Suppresses Prostate Tumor Growth in TRAMP Mice
J. Biol. Chem., September 17, 2004; 279(38): 40076 - 40083.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.